News
ICORG on RTE Radio 1 - Today with Sean O’Rourke Show (29th October 2013)
Dr Ray McDermott [ICORG Clinical Leader] and Dr Janice Walshe were guests on the "Today with Sean O’Rourke" Show on RTE Radio 1 discussing ICORG and Cancer Clinical Trials.
Click here to listen to the interview
If you would like to assist ICORG in the important work we do in Fighting Cancer and bringing new Clinical Treatments to Patients in Ireland through Clinical Trials, please click here to donate.
Your help is hugely appreciated. Thank you.
3rd Irish Melanoma Forum Scientific Meeting - Registration Is Now Open
Registration is now open for the 3rd Irish Melanoma Forum Scientific Meeting.
NCRCI/MTCI Workshop on Endocrine Related Breast Cancer
Save The Date!
NCRCI/MTCI Workshop on Endocrine Related Breast Cancer – 15th November 2013 at 10am.
National Cancer Research Centre of Ireland (NCRCI)
MTCI Foundation and its partners are delighted to announce the inauguration of the National Cancer Research Centre of Ireland (NCRCI).
ICORG has its 4th New England Journal of Medicine Publication
ICORG’s 4th NEJM Publication is now available and it’s exciting news for some Lung Cancer patients.
2 ICORG Studies published in leading Oncology Journals this month
ICORG has 2 first author papers published in leading journals this month – Journal of Clinical Oncology & Annals of Oncology.
Professor John Crown proposes a “virtual” National Cancer Research Centre of Ireland
Prof John Crown will chair a meeting in the Herbert Park hotel tomorrow, Friday 14th of June, to discuss the feasibility a “virtual” National Cancer Research Centre of Ireland.
The event is hosted by Molecular Therapeutics for Cancer Ireland (MTCI) and includes international experts, Sir Philip Cohen from Dundee, Prof Ulrik Ringborg from Sweden and Dr Mel Sorensen from the US, who will provide insight into international models for cancer research centres.
ICORG opens ANGIOPREDICT study in Ireland and Germany
The ANGIOPREDICT prospective translational study is an Exploratory Phase II clinical trial comprising biomarker analysis of oxaliplatin plus fluorouracil/leucovorin (FOLFOX) in combination with bevacizumab (bvz) in first line treatment of metastatic colorectal cancer (CRC) expressing mutant K-ras – AC-ANGIOPREDICT’.